A new report reveals more than 180 companies are actively developing over 200 PD-1 and PD-L1 inhibitors, a class of immunotherapies that boost the immune system to fight cancer. These drugs target various cancers including lung, bladder, liver, and endometrial cancers, with several in late-stage trials. Key players like Merck, Roche, and Pfizer are advancing promising candidates, while regulatory approvals and breakthrough designations signal strong growth potential. This expanding pipeline highlights ongoing innovation and competition in oncology treatments, promising improved patient outcomes and new market opportunities.
Merck shares have risen 45% year-to-date, driven by strong sales of its KEYTRUDA drug and upcoming regulatory milestones. Between September and October, Merck faces several FDA decision deadlines for new drug applications, including WINREVAIR and WEL...
Jim Cramer highlighted a market rotation away from tech and data center stocks toward enterprise software and pharmaceuticals, driven by political opposition to data center construction and bond market volatility. Software companies like ServiceNow, ...
Retirees choosing between Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Real Estate ETF (VNQ) face a clear divergence due to the current high interest rate environment. SCHD, focused on dividend-paying companies with strong cash flow, has outpe...
Moderna shares fell 7% to $135.22 following a sharp rise to a record $176.66, as traders took profits after a 392% gain year-to-date. The pullback is orderly with no new company updates; the recent rally was driven by positive phase 3 melanoma trial ...
